WebSep 8, 2024 · The group randomized to the RNA test underwent testing with the Afirma genomic sequencing classifier; the DNA-RNA group underwent testing with the ThyroSeq v3 multigene genomic classifier. Figure 2. Expected Positive Predictive Value Curves of Molecular Tests View LargeDownload WebNov 3, 2024 · They found that the Afirma GSC identified 30 percent more nodules as benign, compared to the GEC (60 percent vs. 46 percent, respectively) and that use of the Afirma GSC resulted in 41 percent...
Thyroid nodule molecular profiling: The clinical utility of Afirma ...
WebThe Afirma ® Genomic Sequencing Classifier (GSC) was developed and clinically validated to utilize genomic material obtained during the FNA to accurately identify benign nodules among those deemed cytologically indeterminate so that diagnostic surgery can … WebDec 6, 2024 · In 2024, the validation study (VS) of the updated Afirma Genomic Sequencing Classifier (GSC) was published. The 2024 GSC VS was based on a cohort … talim island rizal
Real-World Performance of the Afirma Genomic Sequencing Classifier …
WebMay 10, 2024 · The Afirma Genomic Sequencing Classifier combines RNA sequencing data with machine learning to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in ... WebJul 18, 2024 · Background: The Afirma Gene Expression Classifier (GEC) has been used to further characterize cytologically indeterminate (cyto-I) thyroid nodules into either benign or suspicious categories. However, its relatively low positive predictive value (PPV) limited its use as a classifier for patients with suspicious results. The Afirma Gene … WebJan 1, 2024 · The Afirma Genomic Sequencing Classifier uses whole transcriptome RNA sequencing to identify thyroid nodules as benign or suspicious. The Afirma Xpression Atlas became available in 2024 and reports findings across 593 genes, including 905 variants and 235 fusions. When an alteration is identified, its risk of malignancy and associated … ba summer camps